Interleukins, TNF-α and β-2M in patients with B cell chronic lymphocytic leukemia

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 4, 1998, Pages 445-448

  Mavridis, A K ^a   Tsiara, St ^b   Makis, A ^b   Chaidos, A ^b   Christou, L ^b   Seferiadis, K ^b   Bourantas, K L ^b,c  

^a G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c NONE   (Greece)

Author keywords

2M; B CLL; Interleukins; TNF

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; INTERLEUKINS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032434535     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hallek M., Kuhn-Halle K.I., Emmerich B.: Prognostic factors in chronic lymphocytic leukemia. Leukemia 11 (Suppl. 2): S4-S13, 1997.
2. Aguilar-Santelises M., Loftenius A., Ljungh C. et al.: Serum levels of helper factors (IL-1 alpha, IL-1 b, and IL-6), T cell products (sCD4 and sCD8), sIL-2R and b-2 microglobulin in patients with B-CLL and benign B lymphocytosis. Leuk. Res. 16: 607-13, 1992.
3. Bennefoy J.Y., Denorou M.C., Guillot O., Marteus C.L., Bauchereau J.: Activation of normal human B cells through their antigen receptor induced membranes expression of IL-1 alpha and secretion of IL-1 b. J. Immunol. 143: 864-9, 1989.
4. Aguillar-Santelises M., Magnusson R., Svenson S.B. et al.: Expression of interleukin-1a, interleukin-1b, and interleukin-6 in chronic B lymphocytic leukemia (B-CLL) cells from patients at different stages of disease progression. Clin. Exp. Immunol. 84: 422-8, 1991.
5. Reittie J.E., Yong K.L., Panayiotidis P., Hofbrand A.V.: Interleukin-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B-chronic lymphocytic leukemia. Leuk. Lymphoma 22: 83-90, 1996.
6. Pizzolo G., Chilosi M., Semenzato G.: The soluble interleukin-2 receptor in haematological disorders. Br. J. Haematol. 67: 377-80, 1987.
7. Worman C.P., Cawley J.C.: Monoclonal antibody-defined T cell subsets in hairy-cell leukemia. Scand. J. Haematol. 29: 338-44, 1982.
8. Semenzato G., Foa R., Agostino C., Zambello R., Trentin L., Vinante F., Benedetti F., Pizzolo G.: High serum levels of soluble interleukin-2 receptor in patients with B chronic lymphocytic leukemia. Blood 70: 396-400, 1987.
9. Mainou-Flower T., Copplestone J.A., Prentice A.G.: Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukemia cells. J. Clin. Pathol. 48: 482-7, 1995.
10. Fluckiger A.C., Durand I., Banchereau J.: Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J. Exp. Med. 179: 91-9, 1994.
11. Dahike E., Schlag R., Langenmayer I. et al.: Decreased production of TNF and IL-6 in whole blood of CLL patients. Am. J. Hematol. 49: 76-82, 1995.
12. Grey H.M., Kubo R.T., Colon S.M. et al.: The small subunit of HLA antigens in b 2-microglobulin. J. Exp. Med. 138: 1608-12, 1973.
13. Shuster J., Gold P., Poulik M.D.: Beta 2-microglobulin levels in cancerous and other disease states. Clin. Chim. Acta 67: 307-13, 1976.
14. Pavlidis N.A., Kalef-Ezra J., Bourantas K.L. et al.: Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Int. J. Biol. Markers 8: 14-20, 1993.
15. Brittinger G., Hellrieged K.P., Hiddemann W.: Chronic lymphocytic leukemia and hayr-cell leukemia diagnosis and treatment: results of a consensus meeting of the German CLL cooperative group. Leukemia 11 Suppl. 2: 51-3, 1997.
16. Moberts R., Hoogerbrugge H., van Agthoven T., Lowenberg B., Touw I.: Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and b. Leuk. Res. 13: 973-80, 1989.
17. Marcon L., Rubin L.A., Kurman C.C., Fritz M.E., Longo D.L., Uchivama T., Edwards B.K., Nelson D.L.: Elevated serum levels of soluble Tac peptide in adult T cell leukemia: correlation with clinical status during chemotherapy. Ann. Int. Med. 109: 274-9, 1988.
18. Chilosi M., Pizzolo G., Semenzato G., Cetto G.L.: Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hairy cell leukemia. Int. J. Biol. Markers 1: 101-6, 1986.
19. Greene W.C., Leonard W.J., Depper J.M., Nelson D.L., Waldmann T.A.: The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphocytic retroviruses. Ann. Inter. Med. 105: 560-72, 1986.
20. Child J.A., Spati B., Illingworth S., Barnard D., Corbett S., Simmons A.V., Stone J., Wortly T.S., Cooper E.H.: Serum b2-microglobulin and C-reactive protein in the monitoring of lymphomas. Cancer 45: 318-26, 1980.
21. Litam P., Swan F., Cabanillas F., Tucker S.L., McLaughlin P., Hagemeister F.B., Rodriguez M.A., Velasquez W.Z.: Prognostic value of serum b-2 microglobulin in low-grade lymphoma. Ann. Inter. Med. 114: 855-60, 1991.